HIVVaccineEnterprise

Uniting stakeholders to share knowledge, foster collaboration, enable solutions & expand support critical to the development of, and future access to an HIV vax

[IAS - the International AIDS Society @iasociety]

Yesterday J&J and partners announced the discontinuation of the Imbokodo #HIV Vaccine Trial. Despite this disappointing news, IAS emphasizes the importance of continued investment and engagement in trials to find an effective vaccine. Read our statement: https://t.co/20IU04Hm25

[HIVVaccineEnterprise @HIVEnterprise]

The Imbokodo trial must drive us to adequately join efforts to find an #HIVVaccine. Read the latest IAS Statement on yesterday's decision to cease the large-scale Imbokodo HIV Vaccine Trial: https://t.co/a1MWVLpV5K

[HIVVaccineEnterprise @HIVEnterprise]

Only with an effective HIV vaccine can we overcome bottlenecks of cure and prevention availability especially for vulnerable communities. "There must be a role for community throughout the whole process from start to finish." @EamonnMurphy @UNAIDS

[HIVVaccineEnterprise @HIVEnterprise]

When it comes to the distribution of an HIV vaccine, we need to fight inequalities and should learn from lessons covid taught us
@IAVI

[HIVVaccineEnterprise @HIVEnterprise]

Despite advances in cure and prevention, an HIV vaccine will be the only sustainable way we will really make progress to prevent HIV
@WHO @UNAIDS

[HIVVaccineEnterprise @HIVEnterprise]

we need to reignite the enthusiasm and optimism to build capacity and funding to succeed in the search for an HIV vaccine
@UNAIDS

[HIVVaccineEnterprise @HIVEnterprise]

Will it be too late when we finally find an HIV vaccine? Despite advances in cure and prevention, an HIV vaccine will be the only sustainable way we will really make progress to prevent HIV @UNAIDS #IAS2021

[HIVVaccineEnterprise @HIVEnterprise]

Terrific session with an update on progress so far and the future quest for an HIV vaccine. We need one.
Thanks to the speakers for sharing insightful perspectives!
@Kundai Chinyenze @yazdanpanah_y @rbaggaley @Daisy Ouya @Jerome Singh @Paul Stoffels @UNAIDS @HIVpxresearch

[HIVVaccineEnterprise @HIVEnterprise]

@agenceANRS
Yazdan Yazdanpanah - The huge political commitment during the COVID-19 pandemic, combined with the scientific commitment, is something that was leveraged to develop COVID-19 vaccines. But we should be careful - as we cannot develop an HIV vaccine in 100 days. #IAS2021

[HIVVaccineEnterprise @HIVEnterprise]

@PeterGodfreyFaussett @UNAIDS: We will manage to find ways for funding an HIV vaccine when we have an effective product #IAS2021 There must be a role for community throughout the whole process from start to finish.

[HIVVaccineEnterprise @HIVEnterprise]

Eamonn Murphy from @UNAIDS The sustainability element of an #HIV vaccine is key. We need to harness the momentum, the optimism from the #COVID-19 vaccines, and the make the role of #community central from start to finish. #IAS2021

[HIVVaccineEnterprise @HIVEnterprise]

A HIV vaccine one: do we need one? Critical questions discussed at #IAS2021 session with @UNAIDS live NOW!

[HIVVaccineEnterprise @HIVEnterprise]

Enterprise cosponsored satellite with @UNAIDS #IAS2021 - Tuesday 20 July 7PM CET
https://t.co/1Ltq7WZa2Y

[HIVVaccineEnterprise @HIVEnterprise]

Enterprise cosponsored satellite with @UNAIDS #IAS2021 - Tuesday 20 July 7PM CET
https://t.co/1Ltq7WZa2Y

[HIVVaccineEnterprise @HIVEnterprise]

Clinical Protocol and Population Considerations - ppt download https://t.co/3IQDPo7ZB1

[The Lancet HIV @TheLancetHIV]

Our July issue is out! Featuring #HIV vaccines, PrEP for MSM in west Africa and age patterns of HIV incidence in eastern and southern Africa: https://t.co/AsGfuq7ZLq

Cover by @AsifHazem

[HIVVaccineEnterprise @HIVEnterprise]

BACK TO THE FUTURE: HIV VACCINE LEARNINGS: leading investigators discussed proposed research areas to deepen our understanding of regimens tested in HVTN 702 and other efficacy studies. https://t.co/rIHYEASuvs

[HIVVaccineEnterprise @HIVEnterprise]

BACK TO THE FUTURE: HIV VACCINE LEARNINGS: Introduction to the workshop where Leading investigators discussed proposed research areas to deepen our understanding of regimens tested in HVTN 702 and other efficacy studies. https://t.co/rIHYEASuvs

[HIVVaccineEnterprise @HIVEnterprise]

BACK TO THE FUTURE: HIV VACCINE LEARNINGS: Innate Immune Analyses - Erica Andersen-Nissen, PhD – Cape Town HVTN Immunology Laboratory, Fred Hutchinson Cancer Research Center. https://t.co/rIHYEASuvs

[HIVVaccineEnterprise @HIVEnterprise]

An HIV Vaccine: An Unfulfilled Promise? Listen to Dr. Linda-Gail Bekker and Ms. Maureen Luba discuss why an HIV vaccine remains the ultimate game-changer to ending the epidemic and the gaps it will address in the expanding HIV prevention landscape. https://t.co/JsxIhN1Szw